Sensei Biotherapeutics (NASDAQ:SNSE) Releases Quarterly Earnings Results, Beats Expectations By $1.07 EPS

Sensei Biotherapeutics (NASDAQ:SNSE) announced its earnings results on Monday. The company reported ($3.74) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.81) by $1.07, FiscalAI reports.

Sensei Biotherapeutics Price Performance

NASDAQ:SNSE opened at $27.68 on Monday. The company has a fifty day moving average of $21.21 and a 200-day moving average of $13.77. The firm has a market capitalization of $34.88 million, a P/E ratio of -1.45 and a beta of -0.14. Sensei Biotherapeutics has a twelve month low of $5.00 and a twelve month high of $36.76.

Analysts Set New Price Targets

A number of brokerages have weighed in on SNSE. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a report on Monday, December 29th. Wall Street Zen raised Sensei Biotherapeutics to a “hold” rating in a research note on Saturday, December 27th. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $30.00.

Institutional Investors Weigh In On Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC raised its stake in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,516 shares of the company’s stock after purchasing an additional 1,100 shares during the period. Renaissance Technologies LLC owned 0.91% of Sensei Biotherapeutics worth $123,000 as of its most recent SEC filing. 10.50% of the stock is owned by institutional investors and hedge funds.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.